Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Open-Label Randomized, Parallel, Active-Control Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Metastatic Prostate Cancer

NCT01394263 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT01394263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01394263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Open-Label Randomized, Parallel, Active-Control Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Metastatic Prostate Cancer
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2000
Completion date
December 31, 2003
Enrollment
59 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate, prostate cancer